Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Hormone Molecular Biology and Clinical Investigation

Editor-in-Chief: Chetrite, Gérard S.

Editorial Board: Alexis, Michael N. / Baniahmad, Aria / Beato, Miguel / Bouillon, Roger / Brodie, Angela / Carruba, Giuseppe / Chen, Shiuan / Cidlowski, John A. / Clarke, Robert / Coelingh Bennink, Herjan J.T. / Darbre, Philippa D. / Drouin, Jacques / Dufau, Maria L. / Edwards, Dean P. / Falany, Charles N. / Fernandez-Perez, Leandro / Ferroud, Clotilde / Feve, Bruno / Flores-Morales, Amilcar / Foster, Michelle T. / Garcia-Segura, Luis M. / Gastaldelli, Amalia / Gee, Julia M.W. / Genazzani, Andrea R. / Greene, Geoffrey L. / Groner, Bernd / Hampl, Richard / Hilakivi-Clarke, Leena / Hubalek, Michael / Iwase, Hirotaka / Jordan, V. Craig / Klocker, Helmut / Kloet, Ronald / Labrie, Fernand / Mendelson, Carole R. / Mück, Alfred O. / Nicola, Alejandro F. / O'Malley, Bert W. / Raynaud, Jean-Pierre / Ruan, Xiangyan / Russo, Jose / Saad, Farid / Sanchez, Edwin R. / Schally, Andrew V. / Schillaci, Roxana / Schindler, Adolf E. / Söderqvist, Gunnar / Speirs, Valerie / Stanczyk, Frank Z. / Starka, Luboslav / Sutter, Thomas R. / Tresguerres, Jesús A. / Wahli, Walter / Wildt, Ludwig / Yang, Kaiping / Yu, Qi

4 Issues per year


CiteScore 2017: 2.48

SCImago Journal Rank (SJR) 2017: 1.021
Source Normalized Impact per Paper (SNIP) 2017: 0.830

Online
ISSN
1868-1891
See all formats and pricing
More options …
Ahead of print

Issues

Aromatase in normal and diseased liver

Keigo Murakami
  • Corresponding author
  • Department of Pathology, Tohoku University Hospital, 1-1 Seiryou-machi, Aoba-ku, Sendai 980-8574, Japan, Phone: +81-22-7177440, Fax: +81-22-7177449
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Shuko Hata / Yasuhiro Miki
  • Department of Disaster Obstetrics and Gynecology, International Research Institute of Disaster Science, Tohoku University, Sendai, Japan
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Hironobu Sasano
Published Online: 2018-02-28 | DOI: https://doi.org/10.1515/hmbci-2017-0081

Abstract

Background

A potential correlation between sex hormones, such as androgens and estrogens, and the development and progression of hepatocellular carcinoma (HCC) has been proposed. However, its details, in particular, aromatase status in diseased human liver has remained largely unknown.

Materials and methods

We immunolocalized aromatase, 17β-hydroxysteroid dehydrogenase (17β-HSD) type 1 and 17β-HSD type 2 in a total of 155 cases, consisting of normal liver (n = 10), nonalcoholic steatohepatitis (NASH) (n = 18), primary sclerosing cholangitis (PSC) (n = 6), primary biliary cholangitis (PBC) (n = 13), biliary atresia (n = 18), alcoholic hepatitis (n = 11), hepatitis C virus (HCV) (n = 31), HCV sustained virologic response (HCV-SVR) (n = 10), hepatitis B virus (HBV) (n = 20), HBV sustained virologic response (HBV-SVR) (n = 8) and infants (n = 10).

Results

Immunoreactivity scores of aromatase in HBV (59.5 ± 30.9), HBV-SVR (68.1 ± 33.5) and infants (100.5 ± 36.6) were significantly higher than those in normal liver (26.0 ± 17.1). Scores of 17β-HSD type 1 in any etiology other than HBV (116.3 ± 23.7) and infants (120.0 ± 28.5) were significantly lower than those in normal liver (122.5 ± 8.6). Scores of 17β-HSD type 2 in NASH (74.4 ± 36.6) were significantly lower than those in normal liver (128.0 ± 29.7).

Conclusion

High immunoreactivity scores of aromatase and 17β-HSD type 1 in the patients with HBV suggest a correlation between HBV infection and in situ estrogen synthesis in hepatocytes.

Keywords: aromatase; 17β-hydroxysteroid dehydrogenase; diseased liver; normal liver

References

  • [1]

    Harada N, Ota H, Yoshimura N, Katsuyama T, Takagi Y. Localized aberrant expression of cytochrome P450 aromatase in primary and metastatic malignant tumors of human liver. J Clin Endocrinol Metab. 1998;83:697–702.PubMedGoogle Scholar

  • [2]

    Chen Z, Wang O, Nie M, Elison K, Zhou D, Li M, et al. Aromatase deficiency in a Chinese adult man caused by novel compound heterozygous CYP19A1 mutations: effects of estrogen replacement therapy on the bone, lipid, liver and glucose metabolism. Mol Cell Endocrinol. 2015;399:32–42.CrossrefGoogle Scholar

  • [3]

    Chen SA, Besman MJ, Sparkes RS, Zollman S, Klisak I, Mohandas T, et al. Human aromatase: cDNA cloning, Southern blot analysis, and assignment of the gene to chromosome 15. DNA. 1988;7:27–38.CrossrefPubMedGoogle Scholar

  • [4]

    Peltoketo H, Luu-The V, Simard J, Adamski J. 17Beta-hydroxysteroid dehydrogenase (HSD)/17-ketosteroid reductase (KSR) family; nomenclature and main characteristics of the 17HSD/KSR enzymes. J Mol Endocrinol. 1999;23:1–11.PubMedCrossrefGoogle Scholar

  • [5]

    Bulun SE, Lin Z, Imir G, Amin S, Demura M, Yilmaz B, et al. Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev. 2005;57:359–83.CrossrefPubMedGoogle Scholar

  • [6]

    Simpson ER, Clyne C, Rubin G, Boon WC, Robertson K, Britt K, et al. Aromatase – a brief overview. Annu Rev Physiol. 2002;64:93–127.CrossrefPubMedGoogle Scholar

  • [7]

    Yu MC, Yuan JM, Govindarajan S, Ross RK. Epidemiology of hepatocellular carcinoma. Can J Gastroenterol. 2000;14:703–9.PubMedCrossrefGoogle Scholar

  • [8]

    Ioannou GN, Beste LA, Chang MF, Green PK, Lowy E, Tsui JI, et al. Effectiveness of sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ritonavir/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the Veterans Affairs national health care system. Gastroenterology. 2016;151:457–71.PubMedCrossrefGoogle Scholar

  • [9]

    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.PubMedCrossrefGoogle Scholar

  • [10]

    Giannitrapani L, Soresi M, La Spada E, Cervello M, D’Alessandro N, Montalto G. Sex hormones and risk of liver tumor. Ann N Y Acad Sci. 2006;1089:228–36.CrossrefPubMedGoogle Scholar

  • [11]

    De Maria N, Manno M, Villa E. Sex hormones and liver cancer. Mol Cell Endocrinol. 2002;193:59–63.PubMedCrossrefGoogle Scholar

  • [12]

    Gunson DE, Steele RE, Chau RY. Prevention of spontaneous tumours in female rats by fadrozole hydrochloride, an aromatase inhibitor. Br J Cancer. 1995;72:72–5.PubMedCrossrefGoogle Scholar

  • [13]

    Hany MA, Betts DR, Schmugge M, Schönle E, Niggli FK, Zachmann M, et al. A childhood fibrolamellar hepatocellular carcinoma with increased aromatase activity and a near triploid karyotype. Med Pediatr Oncol. 1997;28:136–8.CrossrefGoogle Scholar

  • [14]

    Muramori K, Taguchi S, Taguchi T, Kohashi K, Furuya K, Tokuda K, et al. High aromatase activity and overexpression of epidermal growth factor receptor in fibrolamellar hepatocellular carcinoma in a child. J Pediatr Hematol Oncol. 2011;33:e195–7.CrossrefGoogle Scholar

  • [15]

    Agarwal VR, Takayama K, Van Wyk JJ, Sasano H, Simpson ER, Bulun SE. Molecular basis of severe gynecomastia associated with aromatase expression in a fibrolamellar hepatocellular carcinoma. J Clin Endocrinol Metab. 1998;83:1797–800.Google Scholar

  • [16]

    Miki Y, Suzuki T, Tazawa C, Yamaguchi Y, Kitada K, Honma S, et al. Aromatase localization in human breast cancer tissues: possible interactions between intratumoral stromal and parenchymal cells. Cancer Res. 2007;67:3945–54.PubMedCrossrefGoogle Scholar

  • [17]

    McCarty KS Jr, Miller LS, Cox EB, Konrath J, McCarty KS Sr. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109:716–21.PubMedGoogle Scholar

  • [18]

    Zhao H, Zhou L, Shangguan AJ, Bulun SE. Aromatase expression and regulation in breast and endometrial cancer. J Mol Endocrinol. 2016;57:R19–33.CrossrefPubMedGoogle Scholar

  • [19]

    Bulun SE, Chen D, Moy I, Brooks DC, Zhao H. Aromatase, breast cancer and obesity: a complex interaction. Trends Endocrinol Metab. 2012;23:83–9.PubMedCrossrefGoogle Scholar

  • [20]

    Koh WP, Yuan JM, Wang R, Govindarajan S, Oppenheimer R, Zhang ZQ, et al. Aromatase (CYP19) promoter gene polymorphism and risk of nonviral hepatitis-related hepatocellular carcinoma. Cancer. 2011;117:3383–92.PubMedCrossrefGoogle Scholar

  • [21]

    Shozu M, Zhao Y, Bulun SE, Simpson ER. Multiple splicing events involved in regulation of human aromatase expression by a novel promoter, I.6. Endocrinology. 1998;139:1610–7.PubMedCrossrefGoogle Scholar

  • [22]

    Simpson ER, Davis SR. Minireview: aromatase and the regulation of estrogen biosynthesis – some new perspectives. Endocrinology. 2001;142:4589–94.PubMedCrossrefGoogle Scholar

  • [23]

    Simpson ER, Zhao Y, Agarwal VR, Michael MD, Bulun SE, Hinshelwood MM, et al. Aromatase expression in health and disease. Recent Prog Horm Res. 1997;52:185–214.PubMedGoogle Scholar

  • [24]

    Harada N. Aberrant expression of aromatase in breast cancer tissues. J Steroid Biochem Mol Biol. 1997;61:175–84.PubMedCrossrefGoogle Scholar

  • [25]

    Zhao Y, Agarwal VR, Mendelson CR, Simpson ER. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology. 1996;137:5739–42.PubMedCrossrefGoogle Scholar

  • [26]

    Zhou J, Gurates B, Yang S, Sebastian S, Bulun SE. Malignant breast epithelial cells stimulate aromatase expression via promoter II in human adipose fibroblasts: an epithelial-stromal interaction in breast tumors mediated by CCAAT/enhancer binding protein beta. Cancer Res. 2001;61:2328–34.PubMedGoogle Scholar

  • [27]

    Yamamoto T, Sakai C, Yamaki J, Takamori K, Yoshiji S, Kitawaki J, et al. Estrogen biosynthesis in human liver-a comparison of aromatase activity for C-19 steroids in fetal liver, adult liver and hepatoma tissues of human subjects. Endocrinol Jpn. 1984;31:277–81.CrossrefPubMedGoogle Scholar

  • [28]

    Carruba G. Aromatase in nontumoral and malignant human liver tissues and cells. Ann N Y Acad Sci. 2009;1155:187–93.CrossrefPubMedGoogle Scholar

  • [29]

    Zhang LS, Yuan F, Guan X, Li J, Liu XL, Sun J, et al. Association of genetic polymorphisms in HSD17B1, HSD17B2 and SHBG genes with hepatocellular carcinoma risk. Pathol Oncol Res. 2014;20:661–6.PubMedCrossrefGoogle Scholar

  • [30]

    Castagnetta LA, Agostara B, Montalto G, Polito L, Campisi I, Saetta A, et al. Local estrogen formation by nontumoral, cirrhotic, and malignant human liver tissues and cells. Cancer Res. 2003;63:5041–5.PubMedGoogle Scholar

  • [31]

    Granata OM, Cocciadifero L, Campisi I, Miceli V, Montalto G, Polito LM, et al. Androgen metabolism and biotransformation in nontumoral and malignant human liver tissues and cells. J Steroid Biochem Mol Biol. 2009;113:290–5.CrossrefPubMedGoogle Scholar

  • [32]

    Yabuuchi I, Kawata S, Tamura S, Ito N, Matsuda Y, Nishioka M, et al. Aromatase activity in human hepatocellular carcinoma. Relationship with the degree of histologic differentiation. Cancer. 1993;71:56–61.PubMedCrossrefGoogle Scholar

  • [33]

    Hata S, Miki Y, Saito R, Ishida K, Watanabe M, Sasano H. Aromatase in human liver and its diseases. Cancer Med. 2013;2:305–15.CrossrefPubMedGoogle Scholar

  • [34]

    Bauer I, Al Sarraj J, Vinson C, Larsen R, Thiel G. Interleukin-1β and tetradecanoylphorbol acetate-induced biosynthesis of tumor necrosis factor α in human hepatoma cells involves the transcription factors ATF2 and c-Jun and stress-activated protein kinases. J Cell Biochem. 2007;100:242–55.CrossrefPubMedGoogle Scholar

  • [35]

    Lu P, Nakamoto Y, Nemoto-Sasaki Y, Fujii C, Wang H, Hashii M, et al. Potential interaction between CCR1 and its ligand, CCL3, induced by endogenously produced interleukin-1 in human hepatomas. Am J Pathol. 2003;162:1249–58.CrossrefPubMedGoogle Scholar

  • [36]

    Liu WC, Liu QY. Molecular mechanisms of gender disparity in hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol. 2014;20:6252–61.CrossrefPubMedGoogle Scholar

About the article

Received: 2017-12-12

Accepted: 2018-01-12

Published Online: 2018-02-28


Author Statement

Research funding: Authors state no funding involved.

Conflict of interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Informed consent: Informed consent is not applicable.

Ethical approval: The conducted research is not related to either human or animals use.


Citation Information: Hormone Molecular Biology and Clinical Investigation, 20170081, ISSN (Online) 1868-1891, DOI: https://doi.org/10.1515/hmbci-2017-0081.

Export Citation

©2018 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Comments (0)

Please log in or register to comment.
Log in